Title |
Single-Domain Antibodies As Therapeutics against Human Viral Diseases
|
---|---|
Published in |
Frontiers in immunology, December 2017
|
DOI | 10.3389/fimmu.2017.01802 |
Pubmed ID | |
Authors |
Yanling Wu, Shibo Jiang, Tianlei Ying |
Abstract |
In full-size formats, monoclonal antibodies have been highly successful as therapeutics against cancer and immune diseases. However, their large size leads to inaccessibility of some epitopes and relatively high production costs. As an alternative, single-domain antibodies (sdAbs) offer special advantages compared to full-size antibodies, including smaller size, larger number of accessible epitopes, relatively low production costs and improved robustness. Currently, sdAbs are being developed against a number of viruses, including human immunodeficiency virus-1 (HIV-1), influenza viruses, hepatitis C virus (HCV), respiratory syncytial virus (RSV), and enteric viruses. Although sdAbs are very potent inhibitors of viral infections, no sdAbs have been approved for clinical use against virial infection or any other diseases. In this review, we discuss the current state of research on sdAbs against viruses and their potential as therapeutics against human viral diseases. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Venezuela, Bolivarian Republic of | 2 | 50% |
Unknown | 2 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 75% |
Scientists | 1 | 25% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 178 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 35 | 20% |
Student > Master | 27 | 15% |
Student > Bachelor | 19 | 11% |
Researcher | 16 | 9% |
Student > Doctoral Student | 8 | 4% |
Other | 20 | 11% |
Unknown | 53 | 30% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 50 | 28% |
Agricultural and Biological Sciences | 21 | 12% |
Immunology and Microbiology | 16 | 9% |
Chemistry | 5 | 3% |
Engineering | 5 | 3% |
Other | 21 | 12% |
Unknown | 60 | 34% |